Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients.
This report describes a safe and effective therapy through adoptive transfer of donor cytomegalovirus (CMV)/Epstein-Barr virus (EBV) immune effector cells. The patients, from 3 to 10 years of age, suffering from hematologic diseases received haploidentical transplantation. All 3 patients developed varying levels of viremia from days 13 to 31 and 2 patients developed CMV-interstitial pneumonitis or interstitial inflammation after transplantation. Tapering down the dose of immunosuppressives together with intensive antivirus therapy and escalated infusions of donor-derived CMV/EBV immune effector cells effectively controlled virus-related diseases. All 3 patients survived and remained CMV/EBV-free 14-16 months after transplantation.
Dong
Lujia
L
Fu Dan University, Institute of Hematology, Shanghai Dao-Pei Hospital, Minhang County, Shanghai, China.
Gao
Zhi-Yong
ZY
Chang
Lung-Ji
LJ
Liang
Yin
Y
Tan
Xi-You
XY
Liu
Jin-Hong
JH
Yu
Xin-Jian
XJ
Yang
Fu-Hung
FH
Xie
Yi
Y
Lu
Dao-Pei
DP
D019264:Adoptive Transfer / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control; D003713:Dendritic Cells / Q000637:transplantation / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000209:etiology / Q000517:prevention & control; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D011292:Premedication / Q000379:methods*; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation / Q000821:virology; D016896:Treatment Outcome